CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions

Purpose of Review To describe the clinical role of CDK 4/6 inhibitors in hormone receptor-positive (HR+) metastatic breast cancer (HR+ MBC) as well as current controversies and evolving areas of research.